We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Kinetics of the Finasteride Prostate Induced Apoptosis

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified April 2007 by Hospices Civils de Lyon.
Recruitment status was:  Active, not recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00130767
First Posted: August 16, 2005
Last Update Posted: April 27, 2007
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Hospices Civils de Lyon
August 12, 2005
August 16, 2005
April 27, 2007
December 2004
Not Provided
Date of the maximum apoptosis in the prostate tissues treated by finasteride
Same as current
Complete list of historical versions of study NCT00130767 on ClinicalTrials.gov Archive Site
  • Molecular mechanisms involved in BPH finasteride induced apoptosis
  • Decrease in the frequency of the hemorrhagic incidents after the surgical procedure in patients with a treatment using finasteride
Same as current
Not Provided
Not Provided
 
Kinetics of the Finasteride Prostate Induced Apoptosis
Kinetics of the Finasteride Prostate Induced Apoptosis
The aim of this study is to evaluate the mechanisms involved in the apoptosis induced by a treatment of finasteride on benign prostate hyperplasia (BPH). Five sets of patients who need a surgical procedure because of low tract urinary symptoms are randomly attributed to one of five sets of treatment: 0, 7, 14, 21 or 28 days of finasteride treatment before the day of the procedure. Prostate histological fragments are conditioned for molecular and histologic studies.
Not Provided
Interventional
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Benign Prostatic Hyperplasia
Drug: finasteride
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
90
Not Provided
Not Provided

Inclusion Criteria:

  • Patients with low tract urinary symptoms needing a surgical procedure
  • No previous treatment with finasteride
  • No androgen deficiency; no prostate cancer suspected.
Sexes Eligible for Study: Male
40 Years to 90 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
France
 
 
NCT00130767
2003.316
Not Provided
Not Provided
Not Provided
Not Provided
Hospices Civils de Lyon
Not Provided
Principal Investigator: Alain RUFFION, MD Hospices Civils de Lyon
Hospices Civils de Lyon
April 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP